Related Experiment Videos
Evaluation of the AIDS dementia complex in clinical trials
1Department of Neurology, University of Minnesota, Minneapolis.
Insights
AIDS dementia complex (ADC) is a common complication of HIV-1 infection. Early assessment and treatment are crucial for managing CNS complications and measuring antiviral drug efficacy.
Area of Science:
- Neurology
- Infectious Diseases
- Pharmacology
Background:
- AIDS dementia complex (ADC) is a significant cause of illness in HIV-1 infected individuals.
- Understanding ADC pathogenesis is crucial for effective treatment and prevention strategies.
Purpose of the Study:
- To evaluate the role of ADC assessment in clinical trials for HIV-1 therapies.
- To explore methods for preventing and treating ADC in HIV-1 patients.
Main Methods:
- Neurological examination and neuropsychological testing are primary methods for ADC assessment.
- Cerebrospinal fluid (CSF) surrogate markers show promise for monitoring treatment response.
- Neuroimaging and neurophysiological tests aid in differential diagnosis.
Main Results:
- Antiviral agents show potential in preventing and treating ADC.
- ADC assessment is valuable for measuring the efficacy of antiviral therapies.
Conclusions:
- ADC management requires a combination of diagnostic and monitoring approaches.
- Objective markers in CSF could enhance treatment monitoring and dose adjustment for CNS HIV-1 infection.
Abstract:
The AIDS dementia complex (ADC) is one of the most common and important causes of morbidity associated with infection by human immunodeficiency virus type 1 (HIV-1). The evaluation of ADC in clinical trials is significant not only because of the clinical impact of this syndrome, but also because of the value of measuring its cardinal features as an index of drug efficacy and because of its emerging role as a major clinical end point. The objectives of therapy include both prevention of ADC in the presymptomatic patient and alleviation of established disease. At present, the pathogenesis of ADC is incompletely understood in several critical aspects, particularly the processes underlying the clinical manifestations of central nervous system (CNS) HIV-1 infection and, further, how such processes are related to systemic disease. Consequently, it is not yet clear to what extent, or in which patients, it is necessary to achieve "therapeutic" drug levels within the CNS. Nevertheless, the assessment of ADC prevention and treatment relies principally on the complementary approach of neurological examination for diagnosis and neuropsychological testing for quantitative serial measurement of treatment effects. Additionally, surrogate markers in cerebrospinal fluid (CSF) may hold promise for objective, rapid assessment of treatment response and dose adjustment. Other measurements, including more routine CSF analysis, neuroimaging, and neurophysiological assessments, are used principally for differential diagnosis rather than for monitoring ADC status. Accumulating experience with available antiviral agents suggests that ADC can be effectively prevented and treated, at least for some period of time, and that assessment of this condition is indeed a valuable approach for measuring antiviral therapy.